Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An overview of chemotherapy for mesothelioma.

Literature DB >> 16325127

An overview of chemotherapy for mesothelioma.

Abstract

Mesothelioma is an extraordinarily challenging disease to treat. While numerous clinical trials testing various chemotherapeutic agents have been conducted over the last several decades, only recently have larger studies proven the efficacy of newer chemotherapy regimens. This article reviews the data regarding specific classes of chemotherapeutic agents. The role of treatment in various disease settings and the difficulty in assessing the benefit of that therapy is discussed. Finally, an update is provided on novel therapeutics being testing in mesothelioma.

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2005 PMID： 16325127 DOI： 10.1016/j.hoc.2005.09.010

Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN： 0889-8588 Impact factor: 3.722

Keyword Cloud
Cited

15 in total

1. New concepts in the treatment of malignant pleural mesothelioma.

Authors: Moshe Lapidot; Samuel Freyaldenhoven; Raphael Bueno
Journal: J Thorac Dis Date: 2018-03 Impact factor: 2.895

2. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Authors: Marc Ladanyi; Marjorie G Zauderer; Lee M Krug; Tatsuo Ito; Robert McMillan; Matthew Bott; Filippo Giancotti
Journal: Clin Cancer Res Date: 2012-07-23 Impact factor: 12.531

3. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.

Authors: Jedd M Hillegass; Steven R Blumen; Kai Cheng; Maximilian B MacPherson; Vlada Alexeeva; Sherrill A Lathrop; Stacie L Beuschel; Jeremy L Steinbacher; Kelly J Butnor; Maria E Ramos-Niño; Arti Shukla; Ted A James; Daniel J Weiss; Douglas J Taatjes; Harvey I Pass; Michele Carbone; Christopher C Landry; Brooke T Mossman
Journal: Int J Cancer Date: 2010-11-03 Impact factor: 7.396

4. Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.

Authors: Ying Wang; Arun K Rishi; Wenjuan Wu; Lisa Polin; Sunita Sharma; Edi Levi; Steven Albelda; Harvey I Pass; Anil Wali
Journal: Mol Cell Biochem Date: 2011-05-19 Impact factor: 3.396

5. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

Authors: Ying Wang; Arun K Rishi; Vineshkumar T Puliyappadamba; Sunita Sharma; Huanjie Yang; Adi Tarca; Q Ping Dou; Fulvio Lonardo; John C Ruckdeschel; Harvey I Pass; Anil Wali
Journal: Cancer Chemother Pharmacol Date: 2009-12-04 Impact factor: 3.333

6. Second generation sequencing of the mesothelioma tumor genome.

Authors: Raphael Bueno; Assunta De Rienzo; Lingsheng Dong; Gavin J Gordon; Colin F Hercus; William G Richards; Roderick V Jensen; Arif Anwar; Gautam Maulik; Lucian R Chirieac; Kim-Fong Ho; Bruce E Taillon; Cynthia L Turcotte; Robert G Hercus; Steven R Gullans; David J Sugarbaker
Journal: PLoS One Date: 2010-05-13 Impact factor: 3.240

An overview of chemotherapy for mesothelioma.

1. New concepts in the treatment of malignant pleural mesothelioma.

2. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

3. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.

4. Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.

5. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

6. Second generation sequencing of the mesothelioma tumor genome.

7. Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.

Review 8. Management options for malignant pleural mesothelioma: clinical and cost considerations.

Review 9. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.

Review 10. Systemic treatments for mesothelioma: standard and novel.